Assenagon Asset Management S.A. Sells 132,980 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Assenagon Asset Management S.A. trimmed its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 47.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 146,992 shares of the company's stock after selling 132,980 shares during the period. Assenagon Asset Management S.A. owned about 0.51% of Establishment Labs worth $5,998,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of Establishment Labs during the first quarter worth $234,000. Toronto Dominion Bank bought a new position in Establishment Labs during the fourth quarter valued at about $24,879,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Establishment Labs by 15.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock valued at $2,196,000 after buying an additional 6,307 shares in the last quarter. Union Square Park Capital Management LLC raised its holdings in Establishment Labs by 47.0% during the fourth quarter. Union Square Park Capital Management LLC now owns 160,000 shares of the company's stock valued at $7,371,000 after buying an additional 51,192 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in Establishment Labs by 650.0% during the fourth quarter. Vestal Point Capital LP now owns 300,000 shares of the company's stock valued at $13,821,000 after buying an additional 260,000 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Needham & Company LLC restated a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a report on Friday. BTIG Research assumed coverage on Establishment Labs in a report on Friday, May 16th. They set a "buy" rating and a $62.00 target price on the stock. Wall Street Zen upgraded Establishment Labs from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Stephens restated an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $52.40.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA traded up $0.32 during midday trading on Friday, hitting $37.44. The company's stock had a trading volume of 659,994 shares, compared to its average volume of 476,157. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -14.51 and a beta of 0.74. The stock's 50 day simple moving average is $33.99 and its 200 day simple moving average is $37.29. Establishment Labs Holdings Inc. has a fifty-two week low of $26.56 and a fifty-two week high of $52.41. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.13. The company had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm's revenue was up 11.3% compared to the same quarter last year. During the same period last year, the business posted ($0.58) earnings per share. As a group, research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.